Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed ... added to its portfolio with a therapy for blood disorders sickle cell disease (SCD) and transfusion ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

In the UK, approximately 17,500 people have sickle cell disease and 300 babies are born with the condition each year. It is a genetic disorder ... two forms of gene therapy were approved for ...

PHC Corporation and CCRM have signed a Master Collaboration Agreement to collaborate on developing primary T-cell expansion ...

Given the remarkable advances seen with gene therapies for sickle cell disease (SCD), it may seem ... to where patients actually live. SCD is a genetic disease inherited by people with African ...